GSK obtains exclusive license to Chem...

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

There are 1 comment on the Medical News story from Jan 6, 2012, titled GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA. In it, Medical News reports that:

ChemoCentryx, Inc., today announced that GlaxoSmithKline has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients ... (more)

Join the discussion below, or Read more at Medical News.

Joan

Toronto, Canada

#1 May 6, 2012

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

ChemoCentryx Discussions

Title Updated Last By Comments
News IPO Preview: ChemoCentryx (May '12) May '12 Robson 1
News GSK licenses experimental arthritis treatment f... (May '12) May '12 Robson 1
News GSK Licenses RA Drug from ChemoCentryx (May '12) May '12 Robson 1
News GSK Exercises Option to License ChemoCentryx's ... (May '12) May '12 Robson 1
News GlaxoSmithKline Exercises Option to License Che... (May '12) May '12 Joan 1
News Drug developer ChemoCentryx has priced its IPO ... (May '12) May '12 Joan 1
News Market Report, "Diabetic Nephropathy - Pipeline... (May '12) May '12 Joan 1
More from around the web